Columbus, OH (March 2023) InfinixBio, a biotechnology company dedicated to advancing novel therapeutics through the regulatory approval process, will present results from their novel cancer therapeutic, developed in cooperation with Ohio University, on Sunday, April 16, at the American Association for Cancer Research (AACR) in Orlando, Florida.
This patented breakthrough technology has a unique mechanism that minimizes adverse side effects while enabling the treatment of presently incurable forms of cancer.
“We are excited to describe our laboratory results in which we used a new form of combination therapy that dramatically reduced the amount of chemotherapy drug being used and eliminated difficult-to-treat pancreatic cancer tumors in 40% of the animals tested,” said Dr. Tom Zupancic, InfinixBio Chief Scientific Officer.
“InfinixBio’s therapeutic was successful in dramatically reducing the growth rate of pancreatic cancer tumors in all of the animals tested,” said Dr. Uday Sandbhor, Senior Scientist and lead project manager for InfinixBio. “The laboratory results that we intend to present at AACR detail the unique and novel way our therapy attacks the tumors and prevents them from growing.”
InfinixBio is a full-service, cost-effective CRO that partners with clients to expand capabilities and meet critical milestones for FDA drug and device regulatory requirements. Its cross-functional interdisciplinary team comprises expert scientists and PhDs operating in multiple BSL Level II labs.
Their Rapid Innovate ModelTM helps companies quickly accelerate technology from early development through preclinical and into the clinical trial phase. InfinixBio currently has over 50 patents, either issued or pending.
To learn more about InfinixBio, please visit www.infinixbio.com.
Media and Partnership Inquiries Contact
Please contact Nick Henderson to discuss this at email@example.com.